sur Galimedix, Inc.
Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment
Galimedix Therapeutics has published new data in the International Journal of Molecular Sciences, revealing the potential of GAL-201 in modifying Alzheimer’s disease progression. The study highlights GAL-201's ability to prevent synaptic damage and improve memory and behavior by targeting amyloid-beta (Aβ) pathologies.
GAL-201, currently in preclinical testing, demonstrated significant improvement in learning and memory in animal models. By targeting Aβ aggregation, it effectively reduces the formation of toxic oligomers, resulting in cognitive improvements. The compound also exhibits anti-inflammatory effects and reduces Aβ plaques, addressing key drivers of Alzheimer’s disease.
Galimedix is also developing GAL-101, closely related to GAL-201, currently in a Phase 1 study, with GAL-101 eye drops being investigated for macular degeneration.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.